

# Cannabinoid hyperemesis syndrome: A result of chronic, heavy *Cannabis* use



© TATIANA MOROZOVA

## Hot showers, marijuana cessation relieve nausea and vomiting

**C**annabis is the most commonly abused drug in the United States. Since 2008, *Cannabis* use has significantly increased,<sup>1</sup> in part because of legalization for medicinal and recreational use. Cannabinoid hyperemesis syndrome (CHS) is characterized by years of daily *Cannabis* use, recurrent nausea, vomiting and abdominal pain, compulsive bathing for symptom relief, and symptom resolution with cessation of use.

Prompt recognition of CHS can reduce costs associated with unnecessary workups, emergency department (ED) and urgent care visits, and hospital admissions.<sup>2,3</sup> This article provides a review of CHS with discussion of diagnostic and management considerations.

### CASE REPORT

#### Nauseated and vomiting—and stoned

Mr. M, age 24, self-presents to the ED complaining of two days of severe nausea, colicky abdominal pain, and nonbloody, non-bilious vomiting, as often as 20 times a day. His symptoms become worse with food, and he has difficulty eating and drinking because of his vomiting. Mr. M reports transient symptom relief when he takes hot showers, and has been taking more than 14 showers a day. He reports similar episodes, occurring every two or three months over the last two years, resulting in several ED visits and three hospital admissions.

Mr. M has smoked two to three joints a day for seven years; he has increased his *Cannabis* use in an attempt to alleviate his symptoms, but isn't sure if doing so was helpful. He denies use of tobacco and other illicit drugs, and reports drinking one to three drinks no more than twice a month. He reports dizziness when standing, but no other symptoms. He does not take any

#### Jie Chen, MD

Psychiatry Resident  
Department of Psychiatry and Behavioral Sciences  
University of Washington  
Seattle, Washington

#### Robert M. McCarron, DO

Associate Professor  
Director, Integrated Medicine and Psychiatry Education  
Director, Pain Psychiatry  
Department of Anesthesiology, Division of Pain Medicine  
Department of Psychiatry and Behavioral Sciences  
Department of Internal Medicine  
University of California, Davis School of Medicine  
Sacramento, California

#### Disclosure

The authors report no financial relationships with any company whose products are mentioned in this article or with manufacturers of competing products.

medications, and medical and psychiatric histories are unremarkable.

Physical exam reveals a thin, uncomfortable, young man. Vital signs were significant for tachycardia and mild orthostatic hypotension. His abdomen was diffusely tender, soft, and nondistended. Urine toxicology is positive for delta-9-tetrahydrocannabinol (THC) only. Labs, including a complete blood count (CBC), basic metabolic panel, liver function tests, and lipase, are within normal limits. Prior workup included abdominal radiographs, abdominal ultrasonography, abdominal CT, and gastric biopsy; all are normal. He has mild gastritis and esophagitis on esophagogastroduodenoscopy and mildly delayed gastric emptying. HIV and hepatitis screenings are negative. Six months ago he received antibiotic therapy for *Helicobacter pylori* infection.

Mr. M is admitted to the hospital and seen by the psychiatric consultation service. He is treated with IV ondansetron and prochlorperazine, with little effect. He showers frequently until his symptoms begin to abate within 36 hours of stopping *Cannabis* use, and is discharged soon after. Psychiatric clinicians provide brief motivational interviewing while Mr. M is in the hospital, and refer him to outpatient psychiatric care and Narcotics Anonymous. Mr. M is then lost to follow up.

In 2011, 18.1 million people reported *Cannabis* use in the previous month; 39% reported use in 20 of the last 30 days.<sup>1</sup> A high rate of use and a relatively low number of cases suggests that CHS is rare. However, it is likely that CHS is under-recognized and under-reported.<sup>2,4,5</sup> CHS symptoms may be misattributed to cyclic vomiting syndrome,<sup>3</sup> because 50% of patients diagnosed with cyclic vomiting syndrome report daily *Cannabis* use.<sup>6</sup> There is no epidemiological data on the incidence or prevalence of CHS among regular *Cannabis* users.<sup>7</sup>

Allen and colleagues first described this syndrome in 2004.<sup>4</sup> Since then, CHS has been documented in a growing number of case reports and reviews,<sup>2,3,5,7-13</sup> yet it continues to be under-recognized. Many CHS patients experience delays in diagnosis—often years—resulting in prolonged suffer-

ing, and costs incurred by frequent ED and urgent care visits, hospital admissions, and unnecessary workups.<sup>2,3,7</sup>

## Clinical characteristics

CHS is characterized by recurrent, hyperemetic episodes in the context of chronic, daily *Cannabis* use.<sup>4</sup> The average age of onset is 25.6 years (range: 16 to 51 years).<sup>3</sup> Ninety-five percent of CHS patients used *Cannabis* daily, for, on average, 9.8 years before symptom onset.<sup>3</sup> The amount of *Cannabis* used, although generally high, is difficult to quantify, and has been described as heavy and hourly in units of blunts, cones, joints, bongs, etc. Patients are most likely to present during acute hyperemetic episodes, which occur in a cyclic pattern, every four to eight weeks,<sup>3</sup> interspersed with symptom-free periods. Three phases have been described:

- prodromal or pre-emetic phase
- hyperemetic phase
- recovery phase.<sup>4,10</sup>

Many patients report a prodromal phase, with one or two weeks of morning nausea, food aversion, preserved eating patterns, possible weight loss, and occasional vomiting. The acute, hyperemetic phase is characterized by severe nausea, frequent vomiting, abdominal pain, and compulsive bathing for temporary symptom relief. In the recovery phase, symptom improvement and resolution occur with cessation of *Cannabis* use.<sup>4,10</sup> Symptom improvement can occur within 12 hours of *Cannabis* cessation, but can take as long as three weeks.<sup>3</sup> Patients remain symptom-free while abstinent, but symptoms rapidly recur when they resume use.<sup>3,4</sup>

*Cannabis* is used as an antiemetic and appetite stimulant for chemotherapy-associated nausea and for anorexia in HIV infection. The pathogenesis of paradoxical hyperemetic symptoms of CHS remain unclear, but several mechanisms have been proposed. The principle active cannabinoid in *Cannabis* is the highly lipophilic compound THC, which binds to cannabinoid type 1 (CB1) and type 2 (CB2) receptors in the CNS and other tissues. It is thought that the antiemetic and

## Clinical Point

CHS patients often present during acute hyperemetic episodes, occurring every four to eight weeks, with symptom-free periods



Discuss this article at  
[www.facebook.com/  
CurrentPsychiatry](http://www.facebook.com/CurrentPsychiatry)



## Cannabinoid hyperemesis syndrome

### Clinical Point

Compulsive, hot bathing for symptom relief was described in 98% of all cases and should be considered pathognomonic

Table 1

## Findings associated with cannabinoid hyperemesis syndrome

Key features
<ul style="list-style-type: none"> <li>• Recurrent episodes of severe nausea and intractable vomiting</li> <li>• Abdominal cramping</li> <li>• Current, heavy <i>Cannabis</i> use for at least 3 months</li> <li>• Learned behavior of compulsive bathing<sup>a</sup> with symptom relief</li> <li>• Symptom resolution with cessation of <i>Cannabis</i> use</li> </ul>
Possible associated features
<ul style="list-style-type: none"> <li>• Polydipsia</li> <li>• Mild leukocytosis</li> <li>• Low grade pyrexia</li> <li>• Hypokalemia, hypochloremia</li> <li>• Elevated (salivary) amylase</li> <li>• Weight loss</li> <li>• Mild gastritis on esophagogastroduodenoscopy</li> <li>• Delayed gastric emptying during acute episodes</li> <li>• Antiemetics generally are ineffective</li> </ul>
<sup>a</sup> Compulsive bathing with symptom relief should be considered pathognomonic
Source: References 2-4,7,8

appetite-stimulating effects of *Cannabis* are mediated by CB1 receptor activation in the hypothalamus. Nausea and vomiting are thought to be mediated by CB1 receptor activation in the enteric nervous system, which causes slowed peristalsis, delayed gastric emptying, and splanchnic vasodilation.<sup>4,14</sup>

In sensitive persons, chronic heavy *Cannabis* use can cause THC to accumulate to a toxic level in fatty tissues, causing enteric receptor binding effects to override the CNS receptor-binding effects.<sup>4</sup> This is supported by case studies describing severe vomiting with IV injection of crude marijuana extract.<sup>15</sup> Nearly 100 different THC metabolites have been identified. The *Cannabis* plant contains more than 400 chemicals, with 60 cannabinoid structures, any of which could cause CHS in toxic concentrations.<sup>4,7</sup> Among them, cannabidiol, a 5-HT1A partial agonist, was shown to

cause vomiting at higher doses in animal studies.<sup>4,7</sup>

## Mechanisms of action

*Cannabis* has been used for centuries, so it is unclear why CHS is only recently being recognized. It may be because of higher THC content through selective breeding of plants and a more selective use of female buds that contain more concentrated THC levels than leaves and stems.<sup>3</sup> Alternately, CHS may be caused by exogenous substances, such as pesticides, additives, preservatives, or other chemicals used in marijuana preparation, although there is little evidence to support this.<sup>3</sup>

The mechanism of symptom relief with hot bathing also is unclear. Patients report consistent, global symptom improvement with hot bathing.<sup>3</sup> Relief is rapid, transient, and temperature dependent.<sup>4</sup> CB1 receptors are located near the thermoregulatory center of the hypothalamus. Increased body temperature with hot bathing may counteract the thermoregulatory dysregulation associated with *Cannabis* use.<sup>4,9</sup> It has been proposed that splanchnic vasodilation might contribute to CHS symptoms. Thus, redistribution of blood from the gut to the skin with warm bathing causes a "cutaneous steal syndrome," resulting in symptom relief.<sup>11</sup>

## Diagnostic approach

Four key features should be present when making a diagnosis of CHS:

- heavy marijuana use
- recurrent episodes of severe nausea, vomiting, and abdominal cramping
- compulsive bathing for transient symptom relief
- resolution of symptoms with cessation of *Cannabis* use.<sup>2,4,8</sup>

Compulsive, hot bathing for symptom relief was described in 98% of all reported cases,<sup>3</sup> and should be considered pathognomonic.<sup>2</sup> CHS patients can present with other symptoms, including polydipsia, mild fever, weight loss, and orthostasis.<sup>3</sup> Although lab studies usually are normal, mild leukocytosis, hypokalemia, hypochloremia, elevated

Table 2

### Initial workup of suspected cannabinoid hyperemesis syndrome<sup>a</sup>

History	<ul style="list-style-type: none"> <li>• Obtain a complete substance use history: clarify onset, frequency, amount, and duration of regular <i>Cannabis</i> use</li> <li>• Establish temporal relationships</li> </ul>
Physical exam	<ul style="list-style-type: none"> <li>• Vital signs with orthostatics</li> <li>• Abdominal exam: diffusely tender, benign</li> <li>• Signs and symptoms of dehydration, mild fever</li> </ul>
Initial studies	<ul style="list-style-type: none"> <li>• Basic labs: urine toxicology screen, complete blood count, basic metabolic panel, liver function tests, amylase, lipase, pregnancy test, urinalysis</li> <li>• Imaging: plain abdominal radiograph</li> </ul>

<sup>a</sup>More extensive workup should be guided by clinical suspicion

Source: References 2,4,7

salivary amylase, mild gastritis on esophagogastroduodenoscopy, and delayed gastric emptying have been described during acute episodes (Table 1).<sup>2-4,7,8</sup>

Diagnosis starts with a history and physical exam, followed by a basic workup geared towards ruling out other causes of acute nausea and vomiting.<sup>2,7</sup> Establish temporal relationships between symptoms, *Cannabis* use (onset, frequency, amount, duration), and bathing behaviors. A positive urine toxicology screen supports a CHS diagnosis and can facilitate discussion of *Cannabis* use.<sup>2</sup> If you suspect CHS, rule out potentially life-threatening causes of acute nausea, vomiting, and abdominal pain, such as intestinal obstruction or perforation, pancreaticobiliary disease, and pregnancy. The initial workup should include a CBC, basic metabolic panel, liver function tests, amylase, lipase, pregnancy test, urinalysis, urine toxicology screen, and abdominal radiographs (Table 2).<sup>2,4,7</sup> The differential diagnosis of recurrent vomiting is broad and should be considered (Table 3, page 52).<sup>2,4,7,16</sup> Further workup can proceed non-emergently, and should be prompted by clinical suspicion.<sup>2,7</sup>

#### Supportive treatment, education

Treatment of acute hyperemetic episodes in CHS primarily is supportive; address dehydration with IV fluids and electrolyte replenishment as needed.<sup>2,4,7</sup> Standard antiemetics, including 5-HT<sub>3</sub> receptor antagonists, D<sub>2</sub> receptor antagonists, and H<sub>1</sub>

receptor antagonists, are largely ineffective.<sup>5,9</sup> Although narcotics have been used to treat abdominal pain, use caution when prescribing because they can exacerbate nausea and vomiting.<sup>7</sup> Case reports have described symptom relief with inpatient treatment with lorazepam<sup>12</sup> and self-medication with alprazolam,<sup>4</sup> but more evidence is needed. A recent case report described prompt resolution of symptoms with IV haloperidol.<sup>13</sup> Treating gastritis symptoms with acid suppression therapy, such as a proton pump inhibitor, has been suggested.<sup>7</sup> Symptoms abate during hospitalization regardless of treatment, marking the progression into the recovery phase with abstinence. There are no proven treatments for CHS, aside from cessation of *Cannabis* use. Treatment should focus on motivating your patient to stop using *Cannabis*.

Acute, hyperemetic episodes are ideal teachable moments because of the acuity of symptoms and clear association with *Cannabis* use. However, some patients may be skeptical about CHS because of the better-known antiemetic effects of *Cannabis*. For such patients, provide informational materials describing CHS and take time to address their concerns or doubts.

Motivational interviewing can help provoke behavior change by exploring patient ambivalence in a directive, patient-focused manner. Randomized controlled trials have documented significant reductions in *Cannabis* use with single-session motivational interviewing, with greater

#### Clinical Point

Treatment of acute hyperemetic episodes is supportive; address dehydration with IV fluids and electrolyte replenishment as needed



## Cannabinoid hyperemesis syndrome

### Clinical Point

Studies have documented significant reductions in *Cannabis* use with single-session motivational interviewing

**Table 3**

## Differential diagnosis of recurrent vomiting

Diagnosis	Key features
Cannabinoid hyperemesis syndrome	<ul style="list-style-type: none"> <li>• Current, heavy <i>Cannabis</i> use, for at least 3 months</li> <li>• Compulsive bathing with symptom relief</li> <li>• Resolution of symptoms with cessation of use</li> </ul>
Psychogenic vomiting	<ul style="list-style-type: none"> <li>• Descriptive term for vomiting closely tied to a specific psychiatric diagnosis, such as: anxiety, depression, somatizing, factitious disorder, or malingering</li> </ul>
Bulimia	<ul style="list-style-type: none"> <li>• Fear of weight gain, body image concerns</li> <li>• Binging/purging</li> </ul>
Cyclic vomiting	<ul style="list-style-type: none"> <li>• Paroxysms of vomiting in a cyclical pattern, unrelated to substance use</li> <li>• Psychological stressors</li> <li>• Personal or family history of migraines</li> </ul>
Migraines	<ul style="list-style-type: none"> <li>• Unilateral headache</li> <li>• Aura, photophobia, phonophobia</li> </ul>
CNS: Tumor, elevated intracranial pressure <sup>a</sup>	<ul style="list-style-type: none"> <li>• Headache</li> <li>• Neurological findings</li> <li>• Imaging findings</li> </ul>
Pancreatitis	<ul style="list-style-type: none"> <li>• Elevated lipase and amylase</li> <li>• Pain radiating to the back</li> </ul>
Biliary disease <sup>a</sup>	<ul style="list-style-type: none"> <li>• Abnormal liver function tests</li> <li>• Right upper quadrant pain associated with eating</li> <li>• Imaging findings</li> </ul>
Bowel obstruction <sup>a</sup> Bowel perforation <sup>a</sup>	<ul style="list-style-type: none"> <li>• Acute onset</li> <li>• +/- Prior abdominal surgery</li> <li>• Imaging findings</li> </ul>
Nephrolithiasis	<ul style="list-style-type: none"> <li>• Severe flank pain, radiating to groin</li> <li>• Gross/microscopic hematuria</li> <li>• Imaging findings</li> </ul>
Pyelonephritis	<ul style="list-style-type: none"> <li>• Flank pain, with costovertebral angle tenderness</li> <li>• Signs of infection: fever, leukocytosis</li> <li>• Dirty urinalysis, urine culture</li> </ul>
Acute intermittent porphyria	<ul style="list-style-type: none"> <li>• Severe, steady, poorly localized abdominal pain</li> <li>• +/- Peripheral neuropathy, psychiatric symptoms</li> <li>• Elevated porphobilinogen</li> </ul>
Addison's disease	<ul style="list-style-type: none"> <li>• Hypotension</li> <li>• Hyperpigmentation</li> <li>• Hyponatremia and hypokalemia</li> </ul>
Diabetic gastroparesis	<ul style="list-style-type: none"> <li>• Poorly controlled diabetes</li> <li>• +/- Neuropathy, nephropathy, retinopathy</li> </ul>
Hyperemesis <sup>a</sup> gravidarum	<ul style="list-style-type: none"> <li>• Pregnancy</li> </ul>
Alcohol use	<ul style="list-style-type: none"> <li>• Chronic alcohol use</li> </ul>
Opioid use	<ul style="list-style-type: none"> <li>• Chronic opioid use</li> </ul>
Chemotherapy	<ul style="list-style-type: none"> <li>• Chemotherapy treatment</li> </ul>
Drug seeking	<ul style="list-style-type: none"> <li>• Drug seeking behaviors</li> <li>• History of drug abuse/dependence</li> </ul>

<sup>a</sup>Emergent causes that should be ruled out  
**Source:** References 2,4,7,16

effect among heavy users.<sup>17</sup> Single-session motivational interviewing showed results comparable to providing drug information and advice, suggesting that education and information are useful interventions.<sup>18</sup> Although these single-session studies ap-

pear promising, they focus on younger users who have not been using *Cannabis* as long as typical CHS patients. Multi-session interventions may be needed to address longstanding, heavy *Cannabis* use in adult CHS patients.

**Cognitive-behavioral therapy.** In a series of randomized controlled trials, motivational enhancement training and cognitive-behavioral therapy (CBT) were effective for *Cannabis* use cessation and maintenance of abstinence.<sup>19</sup>

Although these interventions take more time—six to 14 sessions for CBT and one to four sessions for motivational enhancement training—they should be considered for CHS patients with persistent use.

**References**

1. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Results from the 2011 National Survey on Drug Use and Health: Mental health findings. [http://www.samhsa.gov/data/NSDUH/2k11MH\\_FindingsandDetTables/2K11MHFR/NSDUHmhfr2011.htm](http://www.samhsa.gov/data/NSDUH/2k11MH_FindingsandDetTables/2K11MHFR/NSDUHmhfr2011.htm). Published November 2012. Accessed April 18, 2013.
2. Wallace EA, Andrews SE, Garmany CL, et al. Cannabinoid hyperemesis syndrome: literature review and proposed diagnosis and treatment algorithm. *South Med J*. 2011; 104(9):659-664.
3. Nicolson SE, Denysenko L, Mulcare JL, et al. Cannabinoid hyperemesis syndrome: a case series and review of previous reports. *Psychosomatics*. 2012;53(3):212-219.
4. Allen JH, de Moore GM, Heddle R, et al. Cannabinoid

**Related Resources**

- Motivational interviewing for substance use disorders. [www.motivationalinterview.org](http://www.motivationalinterview.org).
- Danovitch I, Gorelick DA. State of the art treatments for cannabis dependence. *Psychiatr Clin North Am*. 2012; 35(2):309-326.

**Drug Brand Names**

Alprazolam • Xanax	Ondansetron • Zofran
Haloperidol • Haldol	Prochlorperazine
Lorazepam • Ativan	• Compazine

- hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. *Cut*. 2004;53(11):1566-1570.
5. Sontineni SP, Chaudhary S, Sontineni V, et al. Cannabinoid hyperemesis syndrome: clinical diagnosis of an underrecognized manifestation of chronic cannabis abuse. *World J Gastroenterol*. 2009;15(10):1264-1266.
  6. Fajardo NR, Cremonini F, Talley NJ. Cyclic vomiting syndrome and chronic cannabis use. *Am J Gastroenterol*. 2005;100:S343.
  7. Galli JA, Sawaya RA, Friedenberg FK. Cannabinoid hyperemesis syndrome. *Curr Drug Abuse Rev*. 2011;4(4): 241-249.
  8. Sullivan S. Cannabinoid hyperemesis. *Can J Gastroenterol*. 2010;24(5):284-285.
  9. Chang YH, Windish DM. Cannabinoid hyperemesis relieved by compulsive bathing. *Mayo Clin Proc*. 2009;84(1):76-78.

continued

**Clinical Point**

Although CBT and motivational interviewing take more time, they should be considered for CHS patients with persistent use

In this issue and at [CurrentPsychiatry.com](http://CurrentPsychiatry.com)

# Managing Bipolar Depression: An Evidence-Based Approach

Learn about developments in the identification and management of bipolar depression that will put you on the path to evidence-based diagnosis and care of this debilitating condition—including the importance of individualizing therapy.

**Free CME credit available**

This activity is jointly sponsored/co-provided by Global Medical Education, HealthmattersCME, and Postgraduate Institute for Medicine.



Supported by an independent educational grant from Sunovion Pharmaceuticals.

A CME supplement to  
CURRENT PSYCHIATRY

Supplement to  
**Current**  
PSYCHIATRY  
OCTOBER 2013 • VOL 10, NO 10

**FREE 1.0 CME**

Available at [CurrentPsychiatry.com](http://CurrentPsychiatry.com)

**Managing Bipolar Depression: An Evidence-Based Approach**

**B**ipolar disorder is characterized by the cyclical occurrence of elevated (manic or hypomanic) and depressed mood states. The illness, which includes the bipolar I and bipolar II subtypes, evokes a heavy toll in terms of quality of life, functioning, morbidity, comorbidity, and mortality. Depressive episodes and symptoms during bipolar depression are associated with similar or greater psychosocial impairment than corresponding levels of manic or hypomanic symptoms.<sup>1</sup>

Bipolar depression also poses special challenges for diagnosis and treatment, however, until recently, the scientific literature primarily focused on the management of manic episodes and symptoms. Although numerous agents targeting the manic phase of bipolar disorder have received Food and Drug Administration (FDA) approval, there has long been an unmet need for FDA-approved agents in the treatment of bipolar depression (Figure 1). The antidepressant-fluoxetine combination (FCX) and quetiapine XR were FDA-approved for the acute treatment of bipolar depression in 2003 and 2006, respectively. However, treatment options have only very recently expanded with the 2013 approval of risperidone as monotherapy and adjunctive therapy for patients with bipolar I depression. This article discusses new developments in the diagnosis and treatment of bipolar depression in an effort to help physicians follow an evidence-based approach to managing bipolar depression.

**Diagnosis**  
Based on the DSM-IV-TR and DSM-5 criteria, the diagnosis of bipolar I disorder requires at least one full manic or mixed episode, whereas bipolar II disorder requires depressive and hypomanic episodes.<sup>2</sup> In practice, patients display a complex constellation of symptoms during different phases of the illness, increasing the likelihood of misdiagnosis. Changes introduced in the new DSM-5 diagnostic criteria were designed to enhance the accuracy of diagnosis and facilitate earlier detection. A separate chapter in our devoted to bipolar and related disorders.

Other notable changes include:

- "Mixed episodes" has been eliminated. The "with mixed features" specifier has been added to mania or hypomania when depressive features are present, and to depressive episodes in the context of major depressive disorder (unipolar depression or bipolar disorder when features of mania/hypomania are present).
- An antidepressant switching full mania/hypomanic episode emerging during antidepressant treatment and persisting beyond pharmacological treatment effect to meet episode criteria is now indicated to qualify as a manic/hypomanic episode diagnosis.
- The "with anxious features" specifier has been added for manic, hypomanic, and major depressive episodes.<sup>3</sup>
- It remains to be seen how the DSM-5 changes will impact the diagnosis of bipolar illness and bipolar depression. The DSM-5 does not address

Continued on page 10

CONTRIBUTOR PAGE 10

GLOBAL MEDICAL EDUCATION | healthmatterscme | Postgraduate Institute for Medicine | SUNOVION | PIM



## Cannabinoid hyperemesis syndrome

10. Soriano-Co M, Batke M, Cappell MS. The cannabis hyperemesis syndrome characterized by persistent nausea and vomiting, abdominal pain, and compulsive bathing associated with chronic marijuana use: a report of eight cases in the United States. *Dig Dis Sci.* 2010;55(11):3113-3119.
11. Patterson DA, Smith E, Monahan M, et al. Cannabinoid hyperemesis and compulsive bathing: a case series and paradoxical pathophysiological explanation. *J Am Board Fam Med.* 2010;23(6):790-793.
12. Cox B, Chhabra A, Adler M, et al. Cannabinoid hyperemesis syndrome: case report of a paradoxical reaction with heavy marijuana use. *Case Rep Med.* 2012;2012:757696.
13. Hickey JL, Witsil JC, Mycyk MB. Haloperidol for treatment of cannabinoid hyperemesis syndrome [published online April 10, 2013]. *Am J Emerg Med.* 2013;31(6):1003.e5-6. doi: 10.1016/j.ajem.2013.02.021.
14. McCallum RW, Soykan I, Sridhar KR, et al. Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized study. *Aliment Pharmacol Ther.* 1999;13(1):77-80.
15. Vaziri ND, Thomas R, Sterling M, et al. Toxicity with intravenous injection of crude marijuana extract. *Clin Toxicol.* 1981;18(3):353-366.
16. Abell TL, Adams KA, Boles RG, et al. Cyclic vomiting syndrome in adults. *Neurogastroenterol Motil.* 2008;20(4):269-284.
17. McCambridge J, Strang J. The efficacy of single-session motivational interviewing in reducing drug consumption and perceptions of drug-related risk and harm among young people: results from a multi-site cluster randomized trial. *Addiction.* 2004;99(1):39-52.
18. McCambridge J, Slym RL, Strang J. Randomized controlled trial of motivational interviewing compared with drug information and advice for early intervention among young cannabis users. *Addiction.* 2008;103(11):1809-1818.
19. Elkashef A, Vocci F, Huestis M, et al. Marijuana neurobiology and treatment. *Subst Abus.* 2008;29(3):17-29.

## Bottom Line

Cannabinoid hyperemesis syndrome (CHS) is characterized by years of daily, heavy *Cannabis* use, cyclic nausea and vomiting, and compulsive bathing. Symptoms resolve with *Cannabis* cessation. Workup of suspected CHS should rule out life-threatening causes of nausea and vomiting. Acute hyperemetic episodes should be managed supportively. Motivational enhancement therapy or cognitive-behavioral therapy should be considered for persistent *Cannibis* use.



GLOBAL MEDICAL  
EDUCATION

## Timely, unbiased, evidence-based medical education from the world's leading experts

Global Medical Education is an online medical education resource that addresses psychiatric topics from the commonplace to the most critical, through a **library of 700+ concise videos** available on-demand on all major digital devices.

GLOBAL MEDICAL EDUCATION

Search

About GME Videos Faculty Partners Journal Watch Resources Join/Renew GME

BDNF and Schizophrenia  
Oliver Freudenreich, MD, Associate Professor of Psychiatry, (Harvard)  
Category: Schizophrenia

Rating: ☆☆☆☆☆  
No votes yet

Add New Comment Take Quiz

BDNF and Schizophrenia

- Brain-derived neurotrophic factor
  - Neurotrophin family
    - NGF, BDNF, NT-3, NT-4/5
  - Critical role in
    - Neuron survival (name)
    - Neuroplasticity
    - Synaptogenesis
    - Learning
    - Fear memory and extinction
  - Genetics: VAL66MET SNP
  - Receptor: TrkB

Previous Lesson Next Lesson

About GME Videos Faculty Join/Renew GME Resources

All content on this website is provided by copyright. Copyright © 2012 by GME Inc. This website also contains material copyrighted by 3rd parties. GME does not provide medical advice. The website and articles are intended for informational purposes only. They are not a substitute for professional medical advice, diagnosis or treatment. Never ignore professional medical advice in seeking treatment because of something you have read on the GME Website. If you think you may have a medical emergency, immediately call your doctor or dial 911.

To access our videos, go to  
<http://gmeded.com/user/register>

Use discount code: **quadrant**